BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Targets $3 Billion Cartilage Repair Market with Cell-Free Gelrin C
Regentis Biomaterials (NYSE American: RGNT) is positioning its Gelrin C hydrogel as a practical regenerative medicine solution for cartilage damage that could help address the substantial clinical and economic burden associated with knee osteoarthritis (“OA”). Gelrin C is a cell-free, off-the-shelf hydrogel administered in a single 10-minute procedure, designed to support cartilage regeneration while avoiding the multiple surgeries, specialized laboratory processing and higher costs associated with some cell-based therapies. With approximately 470,000 knee cartilage repair procedures performed annually in the U.S., representing an estimated $3 billion market, the company believes Gelrin C could offer a more scalable approach that fits existing surgical…
